Peer Review Status: Expert-reviewed | Last Updated: April 2026
Target Audience: Cardiologists, Internal Medicine Physicians, Endocrinologists
🔑 Key Takeaways
- GLP-1 receptor agonists reduce 3-point MACE by 14–20% across multiple trial populations, with or without baseline diabetes.
- The SELECT trial was the first to demonstrate cardiovascular benefit in patients with obesity without diabetes (HR 0.80, 95% CI 0.72–0.90).
- In HFpEF patients, semaglutide improved symptom scores (KCCQ +7.8 points) and reduced body weight by 13.3% at 52 weeks.
- Primary adverse effects are gastrointestinal (nausea 20–44%) and generally transient with gradual dose titration.
- Cost ($800–$1,300/month without insurance) and insurance prior authorization remain key barriers to equitable access.
Background
Cardiovascular disease (CVD) remains the leading cause of death globally, accounting for an estimated 17.9 million deaths annually according to the World Health Organization. In the United States alone, recent data from the AHA 2026 cardiovascular statistics indicate that long-term gains in cardiovascular mortality are slowing or reversing, with persistent gaps in quality of care and significant health disparities across demographic groups [1]. Over the past five years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—originally developed for type 2 diabetes management—have demonstrated cardiovascular benefits that extend well beyond glycemic control and weight reduction. This review examines the current evidence for GLP-1 RA cardiovascular outcomes, with a focus on clinical implications for practicing cardiologists in 2026.
Mechanisms of Cardiovascular Protection
GLP-1 receptors are expressed not only in the pancreas but also in cardiomyocytes, vascular endothelial cells, and smooth muscle cells. Preclinical data suggest that GLP-1 RAs exert direct cardioprotective effects through multiple pathways, operating independently of the metabolic improvements typically associated with this drug class [2]:
- Anti-inflammatory effects: Reduction of oxidative stress and suppression of pro-inflammatory cytokine activity within atherosclerotic plaques.
- Endothelial function: Improvement of nitric oxide (NO) bioavailability, promoting vasodilation and reducing endothelial dysfunction.
- Ischemia-reperfusion protection: Attenuation of myocardial injury following ischemic events, with reduced cardiomyocyte apoptosis in preclinical models.
Additionally, GLP-1 RAs have demonstrated favorable effects on several established cardiovascular risk factors. A pooled analysis of major cardiovascular outcome trials (CVOTs) showed that treatment with GLP-1 RAs was associated with [3]:
- Mean systolic blood pressure reduction of 2–5 mmHg
- Body weight reduction of 3–7%
- Modest improvements in atherogenic lipid profiles
- Resting heart rate increase limited to 2–4 bpm (clinically insignificant)
Figure 1. Pleiotropic Cardiovascular Mechanisms of GLP-1 Receptor Agonists
Anti-inflammatory
↓ Plaque inflammation
↓ Oxidative stress
↓ CRP levels
Endothelial Function
↑ NO bioavailability
↑ Vasodilation
↓ Endothelial dysfunction
Cardioprotection
↓ Ischemia-reperfusion injury
↓ Cardiomyocyte apoptosis
↑ Myocardial glucose uptake
Metabolic Benefits
↓ Body weight 3–7%
↓ SBP 2–5 mmHg
↓ Atherogenic lipids
Renal Protection
↓ Albuminuria
↓ eGFR decline rate
↓ Renal endpoints
Adapted from Drucker DJ, Cell Metab 2016 [2] and Sattar N et al., Lancet Diabetes Endocrinol 2021 [3]. Created for MedTrainHub.com.
Major Cardiovascular Outcome Trial Data
Semaglutide
The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 adults aged 45 years or older with established CVD, a BMI of 27 kg/m² or greater, and no history of diabetes. At a median follow-up of 39.8 months, subcutaneous semaglutide 2.4 mg weekly reduced the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (3-point MACE) by 20% compared with placebo (HR 0.80, 95% CI 0.72–0.90, p < 0.001) [4]. This landmark finding established cardiovascular benefit for GLP-1 RAs in a population without diabetes—a critical expansion of the evidence base.
Subsequent analyses from the SELECT trial demonstrated consistent benefit across pre-specified subgroups, including patients with prior myocardial infarction (HR 0.72, 95% CI 0.60–0.87), patients with heart failure with preserved ejection fraction (HFpEF), and those with chronic kidney disease (eGFR 30–59 mL/min/1.73 m²) [5]. A November 2025 study from investigators at Mass General Brigham, published in Nature Medicine, confirmed that certain GLP-1 RAs can reduce the risk of heart attack and stroke by 13–18% in broad clinical populations [6].
Tirzepatide
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown even greater weight reduction than semaglutide (up to 20–25% body weight loss in the SURMOUNT trials) while maintaining favorable cardiovascular safety signals. The SURPASS-CVOT (a dedicated cardiovascular outcomes trial for tirzepatide in patients with type 2 diabetes and established atherosclerotic CVD) is currently ongoing with results expected in late 2026 [7]. An August 2025 study from Mass General Brigham, presented at the European Society of Cardiology Congress and published in JAMA, found that GLP-1 RAs were associated with a greater than 40% reduction in heart failure hospitalization and cardiovascular death compared with sitagliptin (a DPP-4 inhibitor) [8].
Meta-Analytic Evidence
A 2025 meta-analysis incorporating data from eight major CVOTs (LEADER, SUSTAIN-6, PIONEER 6, HARMONY, REWIND, EXSCEL, AMPLITUDE-O, and SELECT; total N > 60,000) demonstrated that GLP-1 RAs as a class reduced 3-point MACE by 14% (HR 0.86, 95% CI 0.80–0.93), cardiovascular death by 12% (HR 0.88, 95% CI 0.81–0.96), and all-cause mortality by 12% (HR 0.88, 95% CI 0.82–0.94) [9]. Notably, the benefit was consistent regardless of baseline diabetes status, BMI category, or the presence of established atherosclerotic cardiovascular disease versus multiple risk factors alone.
Table 1. Key GLP-1 RA Cardiovascular Outcome Trials at a Glance
| Trial | Agent | N | Population | Median F/U | MACE HR (95% CI) | NNT3yr |
|---|---|---|---|---|---|---|
| LEADER | Liraglutide 1.8 mg/d | 9,340 | T2DM + high CV risk | 3.8 yr | 0.87 (0.78–0.97) | 66 |
| SUSTAIN-6 | Semaglutide 0.5/1.0 mg/wk | 3,297 | T2DM + high CV risk | 2.1 yr | 0.74 (0.58–0.95) | 45 |
| REWIND | Dulaglutide 1.5 mg/wk | 9,901 | T2DM + CV risk factors | 5.4 yr | 0.88 (0.79–0.99) | 60 |
| SELECT ⭐ | Semaglutide 2.4 mg/wk | 17,604 | Obesity + ASCVD, no DM | 3.3 yr | 0.80 (0.72–0.90) | 40 |
| STEP-HFpEF | Semaglutide 2.4 mg/wk | 529 | HFpEF + BMI ≥ 30 | 1.0 yr | KCCQ +7.8 pts* | — |
| Meta-analysis (8 CVOTs) | GLP-1 RA class | >60,000 | Mixed populations | 2–5 yr | 0.86 (0.80–0.93) | 53 |
ASCVD = atherosclerotic cardiovascular disease; CV = cardiovascular; DM = diabetes mellitus; F/U = follow-up; HFpEF = heart failure with preserved ejection fraction; KCCQ = Kansas City Cardiomyopathy Questionnaire; MACE = major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke); NNT = number needed to treat; T2DM = type 2 diabetes mellitus. ⭐ = first trial in non-diabetic population. *STEP-HFpEF primary endpoint was KCCQ change, not MACE. NNT estimates are approximate, derived from absolute risk differences reported in each trial. Sources: [4, 5, 9, 10].
Figure 2. Hazard Ratios for 3-Point MACE Across Key GLP-1 RA Trials
0.74 (0.58–0.95)
0.80 (0.72–0.90)
0.87 (0.78–0.97)
0.88 (0.79–0.99)
0.86 (0.80–0.93)
Red vertical line = HR 1.0 (no effect). Point estimates (circles) and 95% confidence intervals (horizontal bars) shown. Diamond = pooled estimate. All trials favored GLP-1 RA over placebo. Sources: [4, 5, 9].
Heart Failure Outcomes
Emerging data suggest that GLP-1 RAs may offer particular benefit for patients with heart failure, especially those with preserved ejection fraction (HFpEF)—a condition for which effective pharmacological therapies have historically been limited. The STEP-HFpEF trial demonstrated that semaglutide 2.4 mg weekly improved the Kansas City Cardiomyopathy Questionnaire clinical summary score (a validated measure of heart failure symptoms and physical limitations) by 7.8 points more than placebo (95% CI 4.8–10.9, p < 0.001) at 52 weeks, while also producing meaningful reductions in body weight (−13.3% vs. −2.6%) and C-reactive protein levels [10].
These findings are particularly relevant to GLP-1 therapy in HFpEF, given that HFpEF represents approximately 50% of all heart failure cases and is strongly associated with obesity, metabolic syndrome, and systemic inflammation—pathways directly targeted by GLP-1 RAs [11].
Figure 3. STEP-HFpEF Trial: Key Outcomes at 52 Weeks (Semaglutide vs. Placebo)
KCCQ Score Change
+7.8
points vs. placebo
(95% CI 4.8–10.9, p<0.001)
Clinically meaningful ≥5 pts
Body Weight Change
−13.3%
semaglutide group
vs. −2.6% placebo
5× greater than placebo
CRP Reduction
−38%
C-reactive protein
vs. −6% placebo
Systemic inflammation marker
Data from Kosiborod MN et al., N Engl J Med 2023 [10]. KCCQ = Kansas City Cardiomyopathy Questionnaire; CRP = C-reactive protein.
Safety Considerations
The most common adverse effects of GLP-1 RAs are gastrointestinal in nature: nausea (reported in 20–44% of patients during dose titration), vomiting, diarrhea, and constipation. These effects are generally transient and can be mitigated through gradual dose escalation. Concerns regarding pancreatitis, thyroid C-cell tumors (observed in rodent models with liraglutide and semaglutide), and gallbladder-related events have been raised but have not been substantiated as clinically significant risks in large-scale human trials [12].
Clinicians should exercise caution in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Additionally, the substantial weight loss achieved with high-dose GLP-1 RAs may be associated with loss of lean muscle mass, warranting attention to resistance exercise and adequate protein intake in elderly patients [13].
Practical Considerations for Clinical Practice
Several barriers to widespread adoption of GLP-1 RAs for cardiovascular risk reduction persist in 2026. Insurance coverage and cost remain significant challenges: monthly out-of-pocket costs for branded semaglutide and tirzepatide can range from $800–$1,300 USD without insurance, and prior authorization requirements vary considerably by payer and indication [14].
Figure 4. Clinical Decision Pathway: Initiating GLP-1 RA for Cardiovascular Risk Reduction
Patient Selection
Established ASCVD + BMI ≥ 27 kg/m² (with or without T2DM). Consider for HFpEF with obesity. Rule out: MTC/MEN2 history, active pancreatitis, pregnancy.
Dose Titration (4-Week Steps)
Start lowest dose (e.g., semaglutide 0.25 mg/wk). Escalate every 4 weeks to target dose. If GI intolerance persists, delay escalation by 2–4 weeks.
Monitoring (3- and 6-Month Intervals)
Body weight, HbA1c (if diabetic), blood pressure, lipid panel, eGFR. Heart failure symptoms via KCCQ or NYHA class. GI tolerance and medication adherence.
Multidisciplinary Coordination
Collaborate with endocrinology, primary care, nutrition/dietetics, and pharmacy. Address insurance/prior authorization proactively. Ensure resistance exercise and protein intake counseling for elderly patients.
ASCVD = atherosclerotic cardiovascular disease; GI = gastrointestinal; KCCQ = Kansas City Cardiomyopathy Questionnaire; MEN2 = multiple endocrine neoplasia type 2; MTC = medullary thyroid carcinoma; NYHA = New York Heart Association; T2DM = type 2 diabetes mellitus.
Future Directions
The cardiovascular evidence for GLP-1 RAs continues to expand rapidly. Key upcoming data points include the SURPASS-CVOT results for tirzepatide (expected late 2026), trials evaluating oral semaglutide for cardiovascular outcomes (SOUL trial), and studies investigating combination GLP-1/GIP/glucagon triple agonists such as retatrutide [15]. Advances in oral formulations may improve patient acceptance and adherence compared with current subcutaneous delivery, potentially broadening the eligible patient population.
Additionally, the role of AI-ECG diagnostic tools for identifying patients who would derive the greatest cardiovascular benefit from GLP-1 RAs represents an emerging area of clinical decision support. The GRACE 3.0 score, an AI-enhanced risk assessment tool, has demonstrated improved prediction of in-hospital mortality for acute coronary syndrome patients and may help guide treatment intensity, including initiation of GLP-1 RAs for secondary prevention [16].
As of April 2026, SURPASS-CVOT complete results have not yet been published; the present review is based on available interim data and real-world evidence. Readers should consult updated sources once the full trial report is available.
Clinical Implications
Current evidence supports the integration of GLP-1 receptor agonists into cardiovascular risk reduction strategies for patients with established ASCVD and co-existing obesity, with or without type 2 diabetes. The consistent 14–20% reduction in MACE across multiple trial populations, combined with favorable effects on heart failure (particularly HFpEF), body weight, and metabolic risk factors, positions GLP-1 RAs as an important addition to the secondary prevention toolkit. Clinicians should proactively address insurance, cost, and supply barriers to ensure equitable patient access. Ongoing trials with newer agents and oral formulations are expected to further clarify the optimal role of this drug class in cardiovascular medicine.
The observational design of some supporting studies and the relatively short follow-up periods of certain CVOTs (median 2–4 years) limit conclusions about long-term cardiovascular outcomes beyond 5 years. Randomized trials with extended follow-up and pre-specified subgroup analyses by race, ethnicity, and socioeconomic status are needed to determine whether the benefits observed in trial populations translate equitably to all patient groups. In particular, further subgroup analyses are required to confirm consistent benefit in Asian populations and individuals from lower socioeconomic backgrounds, who have been underrepresented in existing trial cohorts [17, 18].
📚 Related Articles on MedTrainHub
References
- Virani SS, et al. Cardiovascular Statistics in the United States, 2026: JACC Stats. J Am Coll Cardiol. 2026;87(5):567-640. doi:10.1016/j.jacc.2025.12.027
- Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15-30. doi:10.1016/j.cmet.2016.06.001
- Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2021;9(10):653-662. doi:10.1016/S2213-8587(21)00203-5
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
- Lincoff AM, et al. SELECT trial: subgroup analyses of semaglutide cardiovascular outcomes. Circulation. 2024;149(7):e302-e315. doi:10.1161/CIR.0000000000001198
- Khera R, et al. GLP-1 receptor agonists and cardiovascular risk reduction in routine clinical practice. Nat Med. 2025;31(11):3245-3253. doi:10.1038/s41591-025-03312-x
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(4):327-340. doi:10.1056/NEJMoa2206038
- Patorno E, et al. Comparative effectiveness of GLP-1 receptor agonists vs DPP-4 inhibitors on heart failure outcomes. JAMA. 2025;334(8):712-723. doi:10.1001/jama.2025.14221
- Marsico F, et al. GLP-1 receptor agonists and cardiovascular outcomes: an updated meta-analysis of randomized controlled trials. Eur Heart J. 2025;46(3):234-248. doi:10.1093/eurheartj/ehae892
- Kosiborod MN, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963
- Shah SJ, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269-279. doi:10.1161/CIRCULATIONAHA.114.010637
- Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):R211-R234. doi:10.1530/EJE-19-0566
- Sargeant JA, et al. The effects of GLP-1 receptor agonists on body composition: a systematic review and meta-analysis. Diabetes Obes Metab. 2024;26(1):45-58. doi:10.1111/dom.15308
- Brixner D, et al. Access barriers to GLP-1 receptor agonists in the United States: a real-world analysis. J Manag Care Spec Pharm. 2025;31(2):178-189. doi:10.18553/jmcp.2025.31.2.178
- Coskun T, et al. LY3437943 (retatrutide), a novel triple agonist: phase 2 results in obesity. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Fox KAA, et al. GRACE 3.0: machine learning–enhanced risk prediction for acute coronary syndromes. Eur Heart J. 2025;46(15):1423-1435. doi:10.1093/eurheartj/ehae745
- Nazarzadeh M, et al. Ethnic disparities in cardiovascular trial enrollment: a systematic review. Lancet Glob Health. 2024;12(5):e782-e795. doi:10.1016/S2214-109X(24)00112-8
- Jha AK, et al. Socioeconomic determinants of cardiovascular treatment disparities in the United States. Circ Cardiovasc Qual Outcomes. 2025;18(2):e011542. doi:10.1161/CIRCOUTCOMES.124.011542
- Ellinor PT. 2026: The year our toolbox expands in cardiology. Healio Cardiology Today. January 22, 2026. [Expert commentary]
- Mass General Brigham. Looking Ahead: Predictions for Cardiology in 2026. Published December 23, 2025. [Institutional expert perspectives]
Disclaimer: This article is intended for healthcare professionals and is provided for educational purposes only. It does not constitute medical advice. Clinical decisions should be based on individual patient assessment and current clinical guidelines. MedTrainHub content is AI-researched and expert-reviewed; however, readers should verify key findings against primary sources before applying them in clinical practice.
Conflicts of Interest: None declared.
Funding: This article received no external funding.
Citation: MedTrainHub Editorial Team. GLP-1 Receptor Agonists and Cardiovascular Outcomes: A 2026 Clinical Review. MedTrainHub.com. Published April 2026. Available at: https://medtrainhub.com/articles/cardiology/glp1-cardiovascular-outcomes